RELATING TO INSURANCE -- PHARMACY FREEDOM OF CHOICE -- FAIR, COMPETITION AND PRACTICES
Impact
The implications of H7189 could significantly affect state laws governing pharmacy practices and insurance. By imposing requirements on PBMs to provide fair reimbursement and prohibiting anti-competitive behavior, the bill aims to create a more equitable marketplace for pharmacies. This initiative is likely to benefit independent pharmacies facing challenges from larger chain pharmacies and their associated PBMs. Furthermore, by including Medicaid organizations under its provisions, the bill ensures that all eligible pharmacies are treated fairly in Medicaid reimbursement scenarios, potentially improving access to medication for underserved populations.
Summary
House Bill H7189, introduced in January 2026, addresses the role of pharmacy benefit managers (PBMs) in the reimbursement process for pharmacies in Rhode Island. The bill aims to ensure fair reimbursement practices by mandating that non-affiliated pharmacies receive equal financial treatment compared to affiliated pharmacies for the same drugs or services. This legislation seeks to enhance competition and protect independent pharmacies from possible discriminatory practices employed by PBMs, which may favor their own affiliated pharmacies over others due to contractual relationships.
Contention
A point of contention surrounding H7189 may stem from the potential pushback from pharmacy benefit managers and affiliated pharmacy chains who may argue that these regulations could increase their operational costs and stifle their business practices. Advocates for the bill contend that without such reforms, independent pharmacies could continue to struggle against the dominant market position of large PBMs. Supporters argue that fair reimbursement practices are essential for maintaining a diverse healthcare landscape, which ultimately benefits patients through increased access to pharmacy services and products.
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Adds new sections that set forth conditions for pharmacists to prescribe tobacco cessation drug therapies, including education approved by state board of pharmacy. The cessation therapies to be covered by all health insurance carriers on or after 1/1/26.
Adds new sections that set forth conditions for pharmacists to prescribe tobacco cessation drug therapies, including education approved by state board of pharmacy. The cessation therapies to be covered by all health insurance carriers on or after 1/1/26.
Sets controls on Medicaid prescription drug costs by imposing transparency and accountability requirements on managed care organizations (MCOs) and their pharmacy benefit managers (PBMs).
Sets controls on Medicaid prescription drug costs by imposing transparency and accountability requirements on managed care organizations (MCOs) and their pharmacy benefit managers (PBMs).